Sophia Genetics SA
$ 4.60
1.32%
25 Feb - close price
- Market Cap 308,026,000 USD
- Current Price $ 4.60
- High / Low $ 4.67 / 4.46
- Stock P/E N/A
- Book Value 0.89
- EPS -1.12
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.86 %
- 52 Week High 5.70
- 52 Week Low 2.58
About
Sophia Genetics SA (SOPH) is a leading innovator in data-driven medicine, specializing in advanced genomic and clinical data analytics solutions designed to improve patient outcomes and care. Leveraging state-of-the-art machine learning algorithms, the company's platform empowers hospitals and laboratories to decode complex genomic data, enabling personalized treatment strategies particularly in oncology, rare diseases, and hereditary disorders. With a robust international presence and strategic collaborations with top healthcare institutions, Sophia Genetics is dedicated to revolutionizing healthcare through precision medicine, positioning itself at the forefront of the genomics industry.
Analyst Target Price
$7.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-04 | 2025-05-05 | 2025-03-03 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-03-07 |
| Reported EPS | -0.3 | -0.2457 | -0.2601 | -0.1199 | -0.2778 | -0.23 | -0.21 | -0.37 | -0.21 | -0.33 | -0.31 | -0.22 |
| Estimated EPS | -0.23 | -0.22 | -0.195 | -0.15 | -0.23 | -0.28 | -0.27 | -0.27 | -0.32 | -0.31 | -0.32 | -0.36 |
| Surprise | -0.07 | -0.0257 | -0.0651 | 0.0301 | -0.0478 | 0.05 | 0.06 | -0.1 | 0.11 | -0.02 | 0.01 | 0.14 |
| Surprise Percentage | -30.4348% | -11.6818% | -33.3846% | 20.0667% | -20.7826% | 17.8571% | 22.2222% | -37.037% | 34.375% | -6.4516% | 3.125% | 38.8889% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SOPH
2026-02-24 11:54:19
SOPHiA GENETICS (NASDAQ:SOPH) is expected to announce its Q4 2025 earnings before market open on Tuesday, March 3, 2026, with analysts forecasting a loss of $0.20 per share and revenue of $21.2 million. The stock currently trades around $4.60 with a market capitalization of $310.87 million, and institutional investors have significantly increased their positions, owning approximately 31.6% of the company. Analysts have a mixed sentiment with an average "Hold" rating and a consensus price target of $7.00.
2026-02-15 09:57:12
SOPHiA GENETICS SA (NASDAQ:SOPH) saw a significant 44.8% increase in short interest to 76,808 shares as of January 30th, though this still represents only 0.1% of the stock. The company has an average analyst rating of "Hold" with a consensus price target of $7.00, and institutional investors hold about 31.59% of the shares. Several firms recently initiated new positions in SOPH during Q3/Q4.
2026-02-11 07:28:14
SOPHiA GENETICS has announced a significant expansion in the U.S. by partnering with two major integrated health systems. These partnerships will deploy SOPHiA DDM™ to analyze complex genomic data for up to 60,000 patients annually on the West Coast and Midwest, focusing on hereditary cancers and rare diseases. The AI-driven platform aims to accelerate diagnosis, personalize care, streamline operations, and support research initiatives within these large healthcare organizations.
2026-02-10 14:58:05
SOPHiA GENETICS has announced a significant expansion in the United States by partnering with two major integrated health systems. These systems will utilize SOPHiA DDM™ for Enhanced Exome analysis to process up to 60,000 genetic samples annually, aiming to improve diagnosis and personalized care for patients with hereditary cancers and rare diseases. This collaboration reinforces SOPHiA GENETICS' mission to democratize data-driven medicine through AI-powered genomic solutions.
2026-02-10 06:58:02
SOPHiA GENETICS has announced a significant expansion in the U.S. by partnering with two major integrated health systems, including a leading nonprofit multi-region system and a top 10 U.S. health system laboratory. These new collaborations will leverage the AI-native, cloud-based SOPHiA DDM™ platform to analyze complex genomic data for up to 60,000 patients annually, aiming to accelerate diagnoses and personalize care for hereditary cancers and rare diseases. The expansion reinforces SOPHiA GENETICS' commitment to democratizing data-driven medicine and strengthening its presence in the United States.
2026-02-06 14:01:00
SOPHiA GENETICS SA (NASDAQ:SOPH) experienced an 11% stock price drop, causing losses for both individual and institutional investors. Individual investors hold the largest share of the company at 44%, followed by institutions at 31%, with the top 9 shareholders accounting for 50% of the business. Insiders own 22 million USD worth of shares, indicating some alignment of interests with the board.
